...
首页> 外文期刊>Journal of Clinical Microbiology >Point-Counterpoint: Molecular Testing for Infectious Diseases Should Be Done in the Clinical Microbiology Laboratory
【24h】

Point-Counterpoint: Molecular Testing for Infectious Diseases Should Be Done in the Clinical Microbiology Laboratory

机译:点对点:临床微生物学实验室应该对传染病进行分子检测

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Over the past decade, there has been an explosion in the use of molecular tests to diagnose and manage infectious diseases. HIV is a prime example of an infectious agent whose diagnosis at least in the acute stage, susceptibility testing, and management are all dependent on molecular diagnostics. The ability to accurately diagnose a plethora of respiratory pathogens quickly, simply, and relatively inexpensively compared to traditional methods is becoming a reality. Direct sequencing and microarray analysis holds great promise for directly detecting a wide variety of organisms from clinical specimens. The question is where this testing should be done in the clinical laboratory. There are at least four models that have emerged: Molecular infectious disease testing as an arm of the clinical microbiology laboratory Molecular infectious disease testing done in a central molecular pathology laboratory under the leadership of a clinical microbiologist Molecular infectious disease testing done in a central molecular pathology laboratory under the leadership of an individual whose primary interest is in another area of molecular pathology Molecular infectious disease testing sent to a reference laboratory and not done on site or within the institution's health care system. We have asked three individuals who have thought about this very complex issue to share their rationale for supporting one of these models. Frederick Nolte is the Director of Clinical Laboratories and Director of Molecular Pathology at the Medical University of South Carolina, is active in and held several positions of responsibility in AMP (Association of Molecular Pathology) and is Chair of the CLSI's Area Committee for Molecular Methods, Alex McAdam is the Director of the Infectious Diseases Diagnostic Division at Children's Hospital Boston and an editor of this journal, and his colleague, Nima Mosammaparast, is the Assistant Director of the Infectious Diseases Diagnostic Laboratory at Children's Hospital Boston.
机译:在过去的十年中,分子检测在诊断和管理传染病方面的应用呈爆炸式增长。 HIV是感染因子的主要例证,其至少在急性阶段的诊断,药敏测试和管理都取决于分子诊断。与传统方法相比,能够快速,简单且相对便宜地准确诊断大量呼吸道病原体的能力已成为现实。直接测序和微阵列分析在直接从临床标本中检测多种生物具有广阔的前景。问题是该检验应在临床实验室中进行。至少出现了四种模型:作为临床微生物学实验室的一部分进行分子传染病测试,在临床微生物学家的领导下,在中央分子病理实验室进行分子传染病测试,在中央分子病理学中进行分子传染病测试该实验室由个人负责,该实验室主要从事分子病理学的另一个领域的研究,并将分子传染病测试发送给参考实验室,但未在现场或机构的医疗保健系统内进行。我们已经请三位考虑过这个非常复杂问题的个人分享支持这些模型之一的理由。弗雷德里克·诺尔特(Frederick Nolte)是南卡罗来纳州医科大学临床实验室主任和分子病理学主任,活跃于AMP(分子病理学协会)并担任过多个职务,并担任CLSI分子方法研究区域委员会主席,亚历克斯·麦克亚当(Alex McAdam)是波士顿儿童医院传染病诊断科的主任,也是该杂志的编辑,他的同事尼玛·莫萨玛帕拉斯特(Nima Mosammaparast)是波士顿儿童医院传染病诊断实验室的助理主任。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号